Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, NSW, Australia.
Department of Pharmacy, Prince of Wales Hospital, Randwick, Sydney, NSW, Australia.
Anaesthesia. 2023 Oct;78(10):1225-1236. doi: 10.1111/anae.16085. Epub 2023 Jul 6.
Prescription of modified-release opioids for acute postoperative pain is widespread despite evidence to show their use may be associated with an increased risk of adverse effects. This systematic review and meta-analysis aimed to examine the available evidence on the safety and efficacy of modified-release, compared with immediate-release, oral opioids for postoperative pain in adults. We searched five electronic databases from 1 January 2003 to 1 January 2023. Published randomised clinical trials and observational studies on adults who underwent surgery which compared those who received oral modified-release opioids postoperatively with those receiving oral immediate-release opioids were included. Two reviewers independently extracted data on the primary outcomes of safety (incidence of adverse events) and efficacy (pain intensity, analgesic and opioid use, and physical function) and secondary outcomes (length of hospital stay, hospital readmission, psychological function, costs, and quality of life) up to 12 months postoperatively. Of the eight articles included, five were randomised clinical trials and three were observational studies. The overall quality of evidence was low. Modified-release opioid use was associated with a higher incidence of adverse events (n = 645, odds ratio (95%CI) 2.76 (1.52-5.04)) and worse pain (n = 550, standardised mean difference (95%CI) 0.2 (0.04-0.37)) compared with immediate-release opioid use following surgery. Our narrative synthesis concluded that modified-release opioids showed no superiority over immediate-release opioids for analgesic consumption, length of hospital stay, hospital readmissions or physical function after surgery. One study showed that modified-release opioid use is associated with higher rates of persistent postoperative opioid use compared with immediate-release opioid use. None of the included studies reported on psychological function, costs or quality of life.
尽管有证据表明,使用缓释型阿片类药物可能会增加不良反应的风险,但在急性术后疼痛中开具缓释型阿片类药物的处方仍然很普遍。本系统评价和荟萃分析旨在研究与即时释放型口服阿片类药物相比,缓释型口服阿片类药物用于成人术后疼痛的安全性和疗效的现有证据。我们从 2003 年 1 月 1 日至 2023 年 1 月 1 日检索了五个电子数据库。纳入了比较术后接受口服缓释型阿片类药物和口服即时释放型阿片类药物的成年人的随机临床试验和观察性研究。两位评审员独立提取了安全性(不良反应发生率)和疗效(疼痛强度、镇痛药和阿片类药物使用以及身体功能)的主要结局以及次要结局(住院时间、住院再入院、心理功能、成本和生活质量)的数据,随访时间长达术后 12 个月。纳入的 8 篇文章中,有 5 篇是随机临床试验,3 篇是观察性研究。总体证据质量较低。与即时释放型阿片类药物相比,缓释型阿片类药物的不良反应发生率更高(n=645,比值比(95%CI)2.76(1.52-5.04)),疼痛更严重(n=550,标准化均数差(95%CI)0.2(0.04-0.37))。与即时释放型阿片类药物相比,我们的叙述性综述得出结论,缓释型阿片类药物在术后镇痛消耗、住院时间、住院再入院或身体功能方面没有显示出优于即时释放型阿片类药物的优势。一项研究表明,与即时释放型阿片类药物相比,缓释型阿片类药物的持续术后阿片类药物使用发生率更高。纳入的研究均未报告心理功能、成本或生活质量。